诚邀您参加The Oncologist

2019-07-18 WileyHealthScience WileyHealthScience

诚邀您参加The Oncologist "Immuno-Oncology in China"特刊发布会或观看发布会直播。


陆舜教授介绍特刊

在过去的近十年,肿瘤的免疫治疗在全球得到了迅猛的发展。2015年以后,免疫治疗药物相继在中国进入了临床试验,中国的学者在这个过程中积累了自己的经验,通过临床试验和临床实践积累的病人,总结出中国人自己的常见的毒副反应以及处理方法。

在此基础上,以“Immuno-Oncology In China”为主题的The Oncologist 中国特刊经过一年的筹备终于推出。特刊由陆舜教授担任客座主编,邀请了很多著名专家撰写了中国肿瘤免疫研究的不同的方面的文章。


本期特刊封面

诚邀您参加我们于CSCO-长白肿瘤高峰论坛期间举办的特刊发布会

不能亲临现场可扫码二维码观看直播


*所有参加的代表将获得本期特刊及Wiley的精美小礼物。

关于the Oncologist 杂志:


The Oncologist 以乳腺癌肺癌、肝癌和肠道肿瘤为主要内容,以将最新研究进展转化成对癌症患者最好的多维度治疗与关怀为目标,致力于出版关于重要进展的最新综述,原始研究及评论。The Oncologist 杂志将对患者结局的重视与多学科广度放到同一高度,这使它成为医生和研究者的必备学术资源。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1865682, encodeId=e2d6186568266, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Jun 04 14:33:00 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370042, encodeId=5ddc3e004298, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/05/12a5266c80310ee47ca553700511f53c.jpg, createdBy=b5512215816, createdName=永远不放弃, createdTime=Sun Jul 21 09:11:53 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370037, encodeId=8ca83e00376b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Sun Jul 21 07:39:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455153, encodeId=9ed5145515309, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Sat Jul 20 04:33:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037882, encodeId=accd103e882a9, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Thu Jul 18 16:33:00 CST 2019, time=2019-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369884, encodeId=d18e369884fe, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Thu Jul 18 14:21:19 CST 2019, time=2019-07-18, status=1, ipAttribution=)]
    2020-06-04 minlingfeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1865682, encodeId=e2d6186568266, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Jun 04 14:33:00 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370042, encodeId=5ddc3e004298, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/05/12a5266c80310ee47ca553700511f53c.jpg, createdBy=b5512215816, createdName=永远不放弃, createdTime=Sun Jul 21 09:11:53 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370037, encodeId=8ca83e00376b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Sun Jul 21 07:39:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455153, encodeId=9ed5145515309, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Sat Jul 20 04:33:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037882, encodeId=accd103e882a9, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Thu Jul 18 16:33:00 CST 2019, time=2019-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369884, encodeId=d18e369884fe, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Thu Jul 18 14:21:19 CST 2019, time=2019-07-18, status=1, ipAttribution=)]
    2019-07-21 永远不放弃

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1865682, encodeId=e2d6186568266, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Jun 04 14:33:00 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370042, encodeId=5ddc3e004298, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/05/12a5266c80310ee47ca553700511f53c.jpg, createdBy=b5512215816, createdName=永远不放弃, createdTime=Sun Jul 21 09:11:53 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370037, encodeId=8ca83e00376b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Sun Jul 21 07:39:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455153, encodeId=9ed5145515309, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Sat Jul 20 04:33:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037882, encodeId=accd103e882a9, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Thu Jul 18 16:33:00 CST 2019, time=2019-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369884, encodeId=d18e369884fe, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Thu Jul 18 14:21:19 CST 2019, time=2019-07-18, status=1, ipAttribution=)]
    2019-07-21 yydlt

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1865682, encodeId=e2d6186568266, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Jun 04 14:33:00 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370042, encodeId=5ddc3e004298, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/05/12a5266c80310ee47ca553700511f53c.jpg, createdBy=b5512215816, createdName=永远不放弃, createdTime=Sun Jul 21 09:11:53 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370037, encodeId=8ca83e00376b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Sun Jul 21 07:39:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455153, encodeId=9ed5145515309, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Sat Jul 20 04:33:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037882, encodeId=accd103e882a9, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Thu Jul 18 16:33:00 CST 2019, time=2019-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369884, encodeId=d18e369884fe, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Thu Jul 18 14:21:19 CST 2019, time=2019-07-18, status=1, ipAttribution=)]
    2019-07-20 july_977
  5. [GetPortalCommentsPageByObjectIdResponse(id=1865682, encodeId=e2d6186568266, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Jun 04 14:33:00 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370042, encodeId=5ddc3e004298, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/05/12a5266c80310ee47ca553700511f53c.jpg, createdBy=b5512215816, createdName=永远不放弃, createdTime=Sun Jul 21 09:11:53 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370037, encodeId=8ca83e00376b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Sun Jul 21 07:39:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455153, encodeId=9ed5145515309, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Sat Jul 20 04:33:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037882, encodeId=accd103e882a9, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Thu Jul 18 16:33:00 CST 2019, time=2019-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369884, encodeId=d18e369884fe, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Thu Jul 18 14:21:19 CST 2019, time=2019-07-18, status=1, ipAttribution=)]
    2019-07-18 anti-cancer

    谢谢梅斯分享这么多精彩信息

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1865682, encodeId=e2d6186568266, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Jun 04 14:33:00 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370042, encodeId=5ddc3e004298, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/05/12a5266c80310ee47ca553700511f53c.jpg, createdBy=b5512215816, createdName=永远不放弃, createdTime=Sun Jul 21 09:11:53 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370037, encodeId=8ca83e00376b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Sun Jul 21 07:39:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455153, encodeId=9ed5145515309, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Sat Jul 20 04:33:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037882, encodeId=accd103e882a9, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Thu Jul 18 16:33:00 CST 2019, time=2019-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369884, encodeId=d18e369884fe, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Thu Jul 18 14:21:19 CST 2019, time=2019-07-18, status=1, ipAttribution=)]
    2019-07-18 phoebeyan520

    学习了

    0

相关资讯

2016亚太和中东地区儿童重症监护更佳营养治疗共识发布

亚太中东地区儿科重症监护病房(PICU)营养治疗的现状和可用资源与西方国家不同。现有的对危重症儿童营养管理的指南可能不能直接用于这一地区。本文概述了亚太中东共识工作组制定的儿科重症监护环境下营养治疗的共识声明,描述了这一地区独特的挑战和建议。方法与研究设计:系统检索了2004-2014年间的文献,形成了PICU营养应用关键领域的共识声明。本综述重点关注适用于亚太中东地区的证据。推荐的证据和强度的质

DCR: IPAA手术失败后修复重建的成功率与患者储袋功能的完整性十分相关

由于IPAA手术对慢性溃疡性结肠炎患者有着良好的治疗效果,IPAA的修复和重建手术很少见。所以对接受IPAA修复或重建的慢性溃疡性结肠炎患者的手术和功能的结果目前并没有很好的探索。本研究旨在确定接受IPAA修复或重建的慢性溃疡性结肠炎患者预后结局。

Be The Match BioTherapies和Kiadis Pharma宣布战略合作以加速造血干细胞移植疗法

Be The Match BioTherapies是一家为开发和商业化细胞和基因疗法的生物制药公司,Be The Match BioTherapies近日宣布,将与Kiadis Pharma合作,使造血干细胞移植(HSCT)疗法更安全、更有效。

The Lancet:Abbvie口服JAK1抑制剂upadacitinib治疗类风湿性关节炎III期阳性试验结果

AbbVie的口服JAK1选择性抑制剂upadacitinib治疗中度至严重活动性类风湿性关节炎的关键性III期SELECT-MONOTHERAPY临床试验的积极结果,发表在顶尖杂志"The Lancet"上。

欢迎参加The Oncologist “Immuno-Oncology In China”特刊发布会

诚邀您参加The Oncologist "Immuno-Oncology in China"特刊发布会或观看发布会直播。

J Gastroenterology:肿瘤部位对III期结肠癌淋巴结数量的影响与预后的关系

目前文献对结肠癌患者肠系膜淋巴结比(LNR)的预后意义的定义并不一致。本项研究的目的是确定右侧和左侧结肠癌中LNR的适当临界值,并阐明其临床意义。